| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Omalizumab |
| Brand | Xolair® |
| Indication | As an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment. |
| Assessment Process | |
| Rapid review commissioned | 25/03/2014 |
| Rapid review completed | 25/04/2014 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |